Heilongjiang ZBD Pharmaceutical Co., Ltd.
SSE:603567.SS
11.25 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,706.504 | 3,143.513 | 4,219.403 | 4,129.954 | 3,410.855 | 3,296.781 | 2,785.644 | 3,140.872 | 2,391.578 | 2,073.06 | 1,592.911 | 1,414.805 | 1,379.697 | 1,071.278 |
| Cost of Revenue
| 1,215.054 | 1,810.869 | 3,474.628 | 2,763.546 | 1,496.869 | 1,314.171 | 790.511 | 1,355.676 | 848.515 | 454.151 | 588.203 | 471.007 | 568.207 | 470.073 |
| Gross Profit
| 1,491.45 | 1,332.644 | 744.775 | 1,366.408 | 1,913.986 | 1,982.61 | 1,995.133 | 1,785.196 | 1,543.063 | 1,618.909 | 1,004.709 | 943.799 | 811.49 | 601.205 |
| Gross Profit Ratio
| 0.551 | 0.424 | 0.177 | 0.331 | 0.561 | 0.601 | 0.716 | 0.568 | 0.645 | 0.781 | 0.631 | 0.667 | 0.588 | 0.561 |
| Reseach & Development Expenses
| 37.991 | 80.222 | 70.948 | 55.231 | 81.338 | 86.5 | 90.905 | 93.742 | 70.927 | 92.966 | 67.651 | 58.339 | 62.11 | 0 |
| General & Administrative Expenses
| 100.754 | 118.913 | 108.44 | 103.513 | 114.82 | 123.291 | 122.435 | 120.537 | 122.131 | 56.259 | 48.205 | 40.325 | 43.397 | 135.527 |
| Selling & Marketing Expenses
| 213.774 | 678.659 | 611.875 | 646.73 | 737.932 | 849.492 | 888.635 | 652.887 | 602.604 | 492.534 | 117.243 | 102.738 | 101.467 | 87.775 |
| SG&A
| 314.528 | 796.508 | 720.315 | 750.243 | 852.752 | 972.782 | 1,011.07 | 773.425 | 724.735 | 548.792 | 165.449 | 143.063 | 144.864 | 223.301 |
| Other Expenses
| 615.672 | -243.929 | -405.03 | 92.255 | 284.748 | 208.349 | -23.733 | 1.737 | 96.331 | 66.757 | 38.759 | 6.941 | 6.602 | 1.257 |
| Operating Expenses
| 968.191 | 819.148 | 386.233 | 897.729 | 1,218.838 | 1,267.631 | 1,260.875 | 1,062.834 | 1,032.563 | 871.859 | 436.615 | 363.516 | 331.309 | 233.907 |
| Operating Income
| 523.259 | 473.244 | 297.526 | 712.406 | 727.341 | 732.138 | 574.227 | 647.928 | 491.309 | 668.287 | 513.063 | 494.139 | 446.171 | 344.887 |
| Operating Income Ratio
| 0.193 | 0.151 | 0.071 | 0.172 | 0.213 | 0.222 | 0.206 | 0.206 | 0.205 | 0.322 | 0.322 | 0.349 | 0.323 | 0.322 |
| Total Other Income Expenses Net
| 0.213 | 5.102 | 0.958 | -257.66 | -190.091 | -194.81 | -23.733 | 1.737 | 96.191 | 25.439 | 36.957 | 10.067 | -26.039 | 0.609 |
| Income Before Tax
| 523.472 | 478.346 | 298.485 | 454.746 | 537.25 | 537.329 | 550.494 | 649.665 | 587.486 | 693.725 | 550.02 | 500.978 | 451.615 | 345.496 |
| Income Before Tax Ratio
| 0.193 | 0.152 | 0.071 | 0.11 | 0.158 | 0.163 | 0.198 | 0.207 | 0.246 | 0.335 | 0.345 | 0.354 | 0.327 | 0.323 |
| Income Tax Expense
| 87.079 | 10.76 | 107.604 | 121.986 | 99.747 | 131.484 | 87.092 | 126.465 | 90.827 | 113.958 | 85.967 | 76.162 | 67.003 | 49.432 |
| Net Income
| 438.216 | 472.74 | 185.44 | 332.1 | 436.286 | 408.649 | 462.436 | 520.873 | 509.561 | 585.305 | 477.3 | 436.904 | 389.646 | 296.064 |
| Net Income Ratio
| 0.162 | 0.15 | 0.044 | 0.08 | 0.128 | 0.124 | 0.166 | 0.166 | 0.213 | 0.282 | 0.3 | 0.309 | 0.282 | 0.276 |
| EPS
| 0.47 | 0.5 | 0.2 | 0.38 | 0.51 | 0.48 | 0.54 | 0.61 | 0.6 | 1.45 | 0.66 | 0.61 | 0.54 | 0.41 |
| EPS Diluted
| 0.47 | 0.5 | 0.2 | 0.38 | 0.51 | 0.48 | 0.54 | 0.61 | 0.6 | 1.45 | 0.66 | 0.61 | 0.54 | 0.41 |
| EBITDA
| 804.623 | 840.859 | 606.164 | 736.638 | 842.751 | 813.62 | 753.36 | 837.587 | 802.722 | 856.707 | 712.514 | 622.72 | 538.706 | 424.256 |
| EBITDA Ratio
| 0.297 | 0.267 | 0.144 | 0.178 | 0.247 | 0.247 | 0.27 | 0.267 | 0.336 | 0.413 | 0.447 | 0.44 | 0.39 | 0.396 |